Personalized medicine approach for novel microglia-associated genetic variants in Alzheimer's disease

Acronym

PMG-AD

Description of the granted funding

Alzheimer's disease (AD), the main cause of dementia world-wide, is clinically manifested as memory impairment and executive dysfunction. Most of the pathomechanistic studies in AD have so far largely concentrated on neurons, neglecting the role of other brain cells in neurodegeneration. The goal in the PMG-AD is to establish a personalized medicine-based approach for identification of early biomarkers and therapeutic targets in AD by focusing on novel AD-associated genetic variants in ABI3 and PLCG2 genes and consequently utilizing the latest research methodologies, human-based model systems and cohorts, and PET imaging, multilevel omics, integrative bioinformatic and endophenotype analyses to advance understanding of the role of microglia in AD. This new knowledge will advance the identification of novel candidates as personalized medicine-based biomarker and therapeutic targets for AD.
Show more

Starting year

2020

End year

2023

Granted funding


Mikko Hiltunen Orcid -palvelun logo
148 572 €

Role in consortium of the Academy of Finland

Leader

Other consortium parties

Partner
University of Helsinki (334803)
148 272 €

Funder

Research Council of Finland

Funding instrument

Kansainvälinen yhteisrahoitteinen ohjelma

Other information

Funding decision number

334802

Fields of science

Neurosciences

Research fields

Neurotiede

Identified topics

brain, neuroscience